Dr. Agarwal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Gustave L Levy Pl
New York, NY 10029Phone+1 212-659-6500
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2008 - 2010
OtherClass of 2001
Certifications & Licensure
NY State Medical License 2017 - 2026
AZ State Medical License 2010 - 2022
CO State Medical License 2017 - 2019
NV State Medical License 2017 - 2019
CA State Medical License 2017 - 2018
CT State Medical License 2017 - 2018
PA State Medical License 2008 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Publications & Presentations
PubMed
- 12 citationsEffect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G.M. Durie, Mohit Narang
Clinical Lymphoma, Myeloma & Leukemia. 2021-08-29 - 31 citationsMinimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.Kenneth C. Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson
Clinical Cancer Research. 2021-07-28 - 31 citationsDeveloping next generation immunomodulatory drugs and their combinations in multiple myeloma.Anjan Thakurta, William E. Pierceall, Michael Amatangelo, Erin Flynt, Amit Agarwal
Oncotarget. 2021-07-20
Abstracts/Posters
- Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple MyelomaAmit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Amit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM RegistryAmit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Arch Oncology Snares AbbVie, BMS, Xencor Execs to Boost Medical, Clinical ManagementAugust 2nd, 2021- Amazon Data Showed Big Jump in Diversity Among Senior Leaders — After Definition of ‘Executive’ Was LoosenedMay 25th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
